Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Post by RetailRubeon Aug 13, 2014 5:21pm
337 Views
Post# 22838891

Partner Deal Example

Partner Deal ExampleI just read in my Financial Times (Aug 12, pg 19) that a US biotech company announced a partnership agreement with a big pharma company.  I think it is an indication of the type of deal done in the industry.  Our upcoming deal for Urocidin may have similar terms.

MannKind company developed an inhaled version of insulin, which the FDA approved in late June for the US.  On Aug 11th, Mannkind announced the partnership agreement with Sanofi (a French company).  The deal is to "license and develop".  Note that the FDA approval came first, then the partnership.  I assume that means Sanofi didn't share in clinical trial costs.

Sanofi pays $150m upfront to MannKind plus up to $775m of milestone payments in future.  MannKind will do the manufacturing.  The two companies will share the "profits" globally.  Sanofi gets 65% of the profit and MannKind gets 35%.

Bioniche's deal with Palladin is also a profit-sharing arrangement for Canada/Mexico/South-Africa.  Bioniche ships the product to Palladin at no-charge.  The profits are then split according to a [redacted] formula.

MannKind was up 17% on the announcement of the partnership.  I don't know how much they were up in late June when the FDA decision was announced.



<< Previous
Bullboard Posts
Next >>